<DOC>
	<DOCNO>NCT00093483</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide , cytarabine , idarubicin , work different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : This phase I trial study side effect best dose arsenic trioxide give together cytarabine idarubicin treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide , Cytarabine , Idarubicin Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose and/or biologically effective dose arsenic trioxide follow high-dose cytarabine idarubicin patient previously untreated de novo secondary acute myeloid leukemia . OUTLINE : This dose-escalation study arsenic trioxide . Patients stratify accord time accrual ( November 2002 v since November 2002 ) . Patients receive arsenic trioxide IV 1 hour day 1 follow high-dose cytarabine IV 1 hour every 12 hour day 1-6 idarubicin IV 30 minute day 2-4 ( immediately dose 3 , 5 7 cytarabine ) . Patients also receive filgrastim ( G-CSF ) subcutaneously begin 12 hour last dose chemotherapy continue blood count recover . Cohorts 3-6 patient receive escalate dos arsenic trioxide maximum tolerate dose ( MTD ) , current dose use myelodysplastic syndrome acute promyelocytic leukemia , biologically effective dose reach . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . The biologically effective dose define dose 3 patient constitutive STAT3 activity activity negate first dose arsenic trioxide . PROJECTED ACCRUAL : A maximum 40 patient ( 6 stratum I [ accrue November 2002 ] 34 stratum II [ accrue since November 2002 ] accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm de novo secondary acute myeloid leukemia ≥ 20 % blast AND least 1 follow characteristics* : Auer rod Peroxidase sudan black positive blast Chloroacetate esterasepositive diffusely nonspecific esterasepositive blast Presence myeloid immunophenotype multiparameter flow cytometry , include expression one myeloid marker ( CD13 , CD33 ) blast NOTE : *Megakaryocytic leukemia diagnose detection platelet antigen ( e.g . factor VIII , glycoprotein Ib IIb/IIIa ) use monoclonal antibody presence ultrastructural platelet peroxidase No acute promyelocytic leukemia No Philadelphiachromosome positive chronic myeloid leukemia Prior hematologic disorder , include myelodysplastic syndrome , aplastic anemia , paroxysmal nocturnal hemoglobinuria , myeloproliferative disorder allow PATIENT CHARACTERISTICS : Age 18 59 Performance status Not specify Life expectancy More 4 week Hematopoietic Not specify Hepatic Bilirubin ≤ 2 time normal* SGOT ≤ 2 time normal* Alkaline phosphatase ≤ 2 time normal* NOTE : *Unless abnormality directly attributable leukemia Renal Creatinine ≤ 1.5 time normal* NOTE : *Unless abnormality directly attributable leukemia Cardiovascular Cardiac ejection fraction ≥ 45 % * Absolute QT interval ≤ 460 msec potassium &gt; 4.0 mEq/L magnesium &gt; 1.8 mg/dL No myocardial infarction within past 6 month No uncontrolled symptomatic congestive heart failure No angina pectoris No multifocal cardiac arrythmias No severe cardiovascular disease NOTE : *Unless abnormality directly attributable leukemia Other No serious medical psychiatric illness would preclude informed consent limit survival &lt; 4 week No uncontrolled diabetes mellitus No concurrent active malignancy No known hypersensitivity E. coliderived drug preparation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy acute leukemia , except hydroxyurea control white blood cell count Prior chemotherapy antecedent malignancy medical condition allow Endocrine therapy Not specify Radiotherapy Prior radiotherapy antecedent malignancy medical condition allow Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>